Search results
Added:
3 years ago
Congestive heart failure (CHF) is a rapidly growing public health problem, affecting nearly five million people in the US alone, with nearly half a million new cases annually.The prevalence of CHF is highest in the elderly; ten out of every 1,000 persons over age 65 are affected. Anemia has been considered a modifiable comorbidity in heart failure. Utilizing the World Health Organization (WHO)…
View more
Added:
1 year ago
HFSA 22 - In this interview, Dr Juuso Blomster (Precordior Ltd, Turku, FI) joins us to share the results of the REFLECS Trial (NCT04378179), originally presented at HFSA 2022.
This trial aimed to evaluate the Precordior CardioSignal app's efficacy in measuring patients cardiac motion and function in comparison to echocardiography. Over 200 patients were recruited to this observational study.
…
View more
Added:
3 years ago
Cardiac rehabilitation (CR) refers to the provision of a wide range of secondary prevention services to patients with cardiovascular disease. Although exercise training is a core component of any CR program, modern comprehensive CR programs provide a comprehensive approach to disease modification including risk factor modification, nutritional counseling, weight management, and psychosocial…
View more
Added:
3 years ago
Heart failure is the only cardiovascular disease with increasing incidence and mortality.1 Approximately five million Americans have heart failure, with an annual incidence of 10 per 1,000 in individuals over 65 years of age, an already rising demographic segment of society. Heart failure is the most frequent Medicare diagnosis, with most of its cost related to hospitalizations.1,2 Identification…
View more
Added:
7 months ago
ESC 2023 — We are joined onsite by Prof Christian Sohns and Prof Philipp Sommer (Heart and Diabetes Centre, Bad Oyenhausen, DE) to discuss the findings from the CASTLE-HTx trial (NCT04649801).
CASTLE-HTx (Heart and Diabetes Center North-Rhine Westfalia) aimed to determine if atrial fibrillation ablation has beneficial effects on mortality in patients with end-stage heart failure, who are…
View more
Added:
11 months ago
ESC-HFA 23 - Dr Jawad Haider Butt (Copenhagen University Hospital, DK) outlines the findings of a patient-level meta-analysis of the DAPA-HF and DELIVER trials, which studied the safety and effectiveness of dapagliflozin on patients with both peripheral arterial disease and heart failure. These trials covered the spectrum of patients with heart failure.
The findings of this meta-analysis suggest…
View more
Added:
3 years ago
Chronic heart failure (CHF) is a major public health problem in industrialized societies, with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45 and 55, 2-5% between ages 65 and 75, and approximately 10% for patients aged 80 years or more.1-3 Thus, HF is primarily a condition of the elderly, and approximately 80% of…
View more
Added:
3 years ago
Despite important therapeutic improvements in pharmacological and device therapies, the prognosis for patients with advanced cardiovascular disease is poor, even with optimal pharmacological and device management. Heart failure continues to be a major cause of morbidity and mortality in the US. It is the leading medical cause of hospitalization and is expected to result in an estimated direct and…
View more
Added:
3 years ago
In the US, 90% of the one million annual hospitalizations for heart failure (HF) are due to volume overload.1,2 Hypervolemia contributes to HF progression and mortality. Guidelines recommend that therapy for HF patients be aimed at achieving euvolemia. Intravenous loop diuretics induce rapid diuresis that reduces lung congestion and dyspnea. However, the effectiveness of loop diuretics declines…
View more
Added:
3 years ago
Chronic heart failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more.Thus, HF is primarily a condition of the elderly and approximately 80% of patients…
View more
« First